Search Within

Genitourinary Oncology Service

  1. "Oxford University Press"
Formats
  1. Meeting Abstract (256)
  2. Journal Article (139)
  3. Editorial (4)
  4. Review (4)
  5. Book Section (1)
  6. Guidelines (1)
Groups
  1. Solid Tumor Oncology Division (405)
  2. Department of Medicine (403)
  3. Epidemiology and Biostatistics (51)
  4. GSK Faculty (51)
  5. Population Sciences Research Program (39)
  6. Human Oncology and Pathogenesis Program (37)

More Groups

People
  1. Robert Motzer (110)
  2. Howard Scher (47)
  3. Jonathan Rosenberg (47)
  4. Michael Morris (41)
  5. Dean Bajorin (34)
  6. Dana Rathkopf (28)

More People

Years
  1. 2025 (3)
  2. 2024 (42)
  3. 2023 (31)
  4. 2022 (29)
  5. 2021 (28)
  6. 2020 (26)

More Years

Publications
  1. Annals of Oncology (301)
  2. The Oncologist (39)
  3. JNCI: Journal of the National Cancer Institute (35)
  4. JNCI Cancer Spectrum (8)
  5. Neuro-Oncology (6)
  6. Japanese Journal of Clinical Oncology (3)

More Publications

Publishers
  1. Oxford University Press (405)

Results (405)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma
    Meeting Abstract

    Teo, M. Y.; McBride, S.; Gopalan, A.; Benoliel, H.; Eastham, J. A.; Goh, A.; Szmulewitz, R.; Morgans, A. K.; Bubley, G.; Gupta, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Schonhoft, J.; Barnett, E.; Cohn, E. D.; Zhao, J. L.; Carbone, E. A.; Zanone, M. R.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Oudard, S. M.; Bevans, K. B.; Attard, G.; Efstathiou, E.; Flaig, T. W.; Franke, F. A.; Goodman, O. B. Jr; De Giorgi, U.; Pieczonka, C. M.; Yeruva, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
    Meeting Abstract

    Smith, M. R.; Sandhu, S. K.; George, D. J.; Chi, K. N.; Saad, F.; Thiery-Vuillemin, A.; Stahl, O.; Olmos, D.; Danila, D.; Gafanov, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Personal payments from pharmaceutical companies to authors of oncology clinical practice guidelines
    Journal Article

    Mitchell, A. P.; Mishra, A.; Dey, P.; Curry, M. A.; Trivedi, N. U.; Haddadin, M.; Rahman, M. W.; Winn, A. N.; Dusetzina, S. B.; Bach, P. B.
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors
    Journal Article

    Funt, S. A.; McHugh, D. J.; Tsai, S.; Knezevic, A.; O'Donnell, D.; Patil, S.; Silber, D.; Bromberg, M.; Carousso, M.; Reuter, V. E.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
    Journal Article

    Barrios, D. M.; Phillips, G. S.; Geisler, A. N.; Trelles, S. R.; Markova, A.; Noor, S. J.; Quigley, E. A.; Haliasos, H. C.; Moy, A. P.; Schram, A. M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Inferences about drug safety in phase III trials in oncology: Examples from advanced prostate cancer
    Journal Article

    Drago, J. Z.; Gönen, M.; Thanarajasingam, G.; Sacks, C. A.; Morris, M. J.; Kantoff, P. W.; Stopsack, K. H.
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save